Cas:84639-84-9 7-Hydroxyindole-2-carboxylic acid manufacturer & supplier

Chemical Name:7-Hydroxyindole-2-carboxylic acid

CAS.NO:84639-84-9

Synonyms:1H-Indole-2-carboxylic acid, 7-hydroxy-;7-Hydroxy-1H-indole-2-carboxylic acid;7-Hydroxyindole-2-carboxylic acid;MFCD03839853

Molecular Formula:C₉H₇NO₃

Molecular Weight:177.157

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:511.4±30.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.780

PSA:73.32000

Exact Mass:177.042587

LogP:1.57

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Indole-2-carboxylic acid, 7-hydroxy- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD03839853 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-Hydroxyindole-2-carboxylic acid Use and application,MFCD03839853 technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 7-Hydroxyindole-2-carboxylic acid manufacturer This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. 7-Hydroxyindole-2-carboxylic acid supplier This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. 7-Hydroxyindole-2-carboxylic acid vendor Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 7-Hydroxyindole-2-carboxylic acid factory Alira’s work spans the gamut from transaction advisory to regulatory services to advanced analytics, management consulting, product development and clinical investigator training, to name a few. With the CROS NT deal, Alira secures not only a biometrics presence but also a portfolio of electronic data capture systems.